B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

Ann Rheum Dis. 2022 Jan;81(1):143-145. doi: 10.1136/annrheumdis-2021-220549. Epub 2021 Sep 23.
No abstract available

Keywords: Biological Therapy; Covid-19; Rituximab; Therapeutics.

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Abatacept / adverse effects
  • Administration, Intravenous
  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antirheumatic Agents / adverse effects*
  • Arthritis / drug therapy*
  • B-Lymphocytes
  • Biological Products / administration & dosage
  • Biological Products / adverse effects*
  • Biological Products / therapeutic use
  • COVID-19 / chemically induced*
  • Female
  • Hospitalization
  • Humans
  • Infliximab / adverse effects
  • Male
  • Middle Aged
  • Patient Acuity
  • Risk Factors
  • Rituximab / adverse effects
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Biological Products
  • Rituximab
  • Abatacept
  • Infliximab
  • tocilizumab